1. Oral or intraperitoneal butyrate augments oxaliplatin efficacy in animal models;2. Clinical data show higher serum butyrate in oxaliplatin-responsive cancer patients;3. Preclinical combination of butyrate with anti-programmed cell death ligand 1 (PD-L1) immunotherapy enhances antitumor effects. This evidence concerns the gene CD274 and cancer.